Deborah M. Stephens,
DO
Languages Spoken: English, Spanish
Languages Spoken: English, Spanish
Deborah Stephens, DO joined the Division of Hematology and Hematologic Malignancies as an Assistant Professor in 2014. She completed her internal medicine residency at Cleveland Clinic and fellowship training at Ohio State University. Dr. Stephens’s clinic focuses on patients with chronic lymphocytic leukemia (CLL) and lymphoma. Her primary research interests include developing new targeted therapies for patients with CLL and lymphoma, studying resistance to current therapies, and developing supportive therapies for complications of CLL.. She is the Physician Leader of the Hematology Clinical Trials Division at Huntsman Cancer Institute and is the principal investigator on multiple clinical trials there. Her research has been widely published in influential journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. She is a member of the editorial board for the Journal of Clinical Oncology. On a national level, she is an expert panelist for the National Comprehensive Cancer Network (NCCN) CLL Guidelines Panel, which establishes and published the most widely referenced guidelines for the evaluation and treatment of patients with CLL. Dr. Stephens is the Physician Leader of the SWOG CLL Working Group Committee, which is a group of CLL experts from academic centers around the country who plan and implement national clinical trials to improve the standard-of-care for CLL patients across the country. Dr. Stephens is also a member of the medical board for the CLL Society, which is the largest patient-led CLL group in the country. The sum of Dr. Stephens's experiences demonstrate her deep commitment to improve the care of patients with CLL and lymphoma.
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor |
| Academic Divisions | Hematology/BMT |
| Board Certification | American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.9/ 5
Care provider's explanation of condition/problem
4.9/ 5
Care provider's effort to include me in decisions
4.9/ 5
Wait time at clinic
4.2/ 5
Care provider's concern for questions & worries
4.9/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
October 04, 2021
HUNTSMAN CANCER CENTER
Dr. Stephens for President
UofU Patient
August 29, 2021
HUNTSMAN CANCER CENTER
I recommend Huntsman and dr Stevens every chance I get
UofU Patient
August 13, 2021
HUNTSMAN CANCER CENTER
Dr. Stephens is an outstanding physician. She is very approachable, caring and knowledgeable.
UofU Patient
August 05, 2021
HUNTSMAN CANCER CENTER
Good
UofU Patient
July 01, 2021
HUNTSMAN CANCER CENTER
Dr. D. Stephens was FABULOUS!!!! She listened, she was kind, she was extremely knowledgeable!!! Its difficult to explain how great she was on multiple levels! I left Huntsman so relieved, and informed!!
UofU Patient
May 21, 2021
HUNTSMAN CANCER CENTER
excellent
UofU Patient
May 20, 2021
HUNTSMAN CANCER CENTER
Dr. Stephens has always been kind and compassionate in my care.
UofU Patient
May 03, 2021
HUNTSMAN CANCER CENTER
Dr Stevens was very very concise and very detailed in the explanations of my treatment plan and things that I should do
UofU Patient
May 01, 2021
HUNTSMAN CANCER CENTER
I am very grateful to be under the care of Dr. Stephens
UofU Patient
April 16, 2021
HUNTSMAN CANCER CENTER
Really like Dr Stephens, very caring, kind, and comes across as being very genuine.
UofU Patient
March 29, 2021
HUNTSMAN CANCER CENTER
Dr. Stephens is superlative in every respect. She is the gold-standard for patient care, compassion, patience, competence, expertise, and listening.
UofU Patient
March 25, 2021
HUNTSMAN CANCER CENTER
Great
UofU Patient
March 18, 2021
HUNTSMAN CANCER CENTER
Deborah Stephens was very caring. In fact, she wrote in longhand the information she wanted me to understand about CLL. That is the first I have seen a care provider go to such lengths to be understood. My kudos to Deborah Stephens.
UofU Patient
March 04, 2021
HUNTSMAN CANCER CENTER
I have been dealing with CLL for 23 years. This was the most satisfying and worthwhile visit I have had with a doctor concerning my condition in that entire time.
UofU Patient
February 26, 2021
HUNTSMAN CANCER CENTER
Dr Stephen's is an exceptional caregiver: top in her field, listens to the patient, clear in discussing care options and in answering questions. She has a good sense of humor and takes all the need time for the patient and she is supported with the incredible resources The Huntsman has to offer.
UofU Patient
January 28, 2021
HUNTSMAN CANCER CENTER
I've never had such professional compassion care
UofU Patient
January 17, 2021
HUNTSMAN CANCER CENTER
Doctor Deborah Stephens is a gifted, caring, intelligent Doctor and an even better compassionate women. I literally have quick grown to totally trust her in providing me the best care and options for treatment when the time comes. I consider this more than just a coincidence.
UofU Patient
January 07, 2021
HUNTSMAN CANCER CENTER
very pleased
UofU Patient
December 24, 2020
HUNTSMAN CANCER CENTER
best care around
UofU Patient
December 17, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
December 14, 2020
HUNTSMAN CANCER CENTER
You all are "AWESOME"
UofU Patient
December 05, 2020
HUNTSMAN CANCER CENTER
They are all great to work with.
UofU Patient
December 01, 2020
HUNTSMAN CANCER CENTER
Dr. Stephens is amazing! She is very caring and knowledgeable. In addition, she takes the time to answer all my questions and includes me in decisions. I have complete confidence in her care and I highly recommend her to others.
UofU Patient
November 29, 2020
HUNTSMAN CANCER CENTER
Dr. Stephen's is outstanding!
UofU Patient
November 17, 2020
HUNTSMAN CANCER CENTER
they were very rhoroufh
UofU Patient
October 11, 2020
HUNTSMAN CANCER CENTER
If all doctors were as good as Doctor Stephens all patients would have great care.
UofU Patient
October 09, 2020
HUNTSMAN CANCER CENTER
only the very best
UofU Patient
October 04, 2020
HUNTSMAN CANCER CENTER
Dr Stephens is great. She works with me, not on me.
UofU Patient
August 30, 2020
HUNTSMAN CANCER CENTER
Doctor Stephens is agreat care provider. Thanks
UofU Patient
August 16, 2020
HUNTSMAN CANCER CENTER
Deborah Stephens is the best care provider I've ever been to . All her patients are blessed by being in her care.
UofU Patient
August 10, 2020
HUNTSMAN CANCER CENTER
Very caring and informative
UofU Patient
August 10, 2020
HUNTSMAN CANCER CENTER
Renee Vadenpour (sp), DNP and Deborah Stephens, DO, Hematology and Oncology, are the consummate professionals. Each is caring, supportive and highly regarded by this patient.
UofU Patient
August 02, 2020
HUNTSMAN CANCER CENTER
Excellent care! Competent, understanding, clear and reasoned path forward.
UofU Patient
July 23, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
June 28, 2020
HUNTSMAN CANCER CENTER
This was first visit. Of course I was fearful and probably asked a lot of not especially well-informed questions. I was dealt with most professionally, courteously and patiently.
UofU Patient
June 28, 2020
HUNTSMAN CANCER CENTER
I love this team of doctors. It was good to see Dr Stephens and Renee. I feel they really care.
UofU Patient
June 21, 2020
HUNTSMAN CANCER CENTER
they were able to give all the options available.
UofU Patient
June 21, 2020
HUNTSMAN CANCER CENTER
Dr Stephens was awesome. she listened and she explained things in terms i could understand
UofU Patient
June 17, 2020
HUNTSMAN CANCER CENTER
Dr Stephens was very thorough in answering questions about my condition.
UofU Patient
June 05, 2020
HUNTSMAN CANCER CENTER
Natalie and Dr. Stephens are wonderful
UofU Patient
May 22, 2020
HUNTSMAN CANCER CENTER
Dr Stephens and nurse Renee are just the best!!!!!!
UofU Patient
April 12, 2020
HUNTSMAN CANCER CENTER
Dr Stephens is always caring and listening
UofU Patient
March 22, 2020
HUNTSMAN CANCER CENTER
She truly is the best doctor I have had the pleasure to meet in my long medical history. And I have been fortunate to know many great people along the way.She has a sincere reality about her manner . The way she administers seems like she is a friend, a classmate, coworker or cousin, someone close enough so you feel comfortable around her. She remembers details about your life. She doesnt speak down or brush of questions/concerns. she is pleasant which is always a bonus for patients who are struggling with the disease, who might be fearful, panicked, or hopeless. There are also times when she might be having a day as well, stress or whatever. She doesnt hide it, she is honest. I like that. Yet she also doesnt let it get in the way of her care of the patient, so even still she shines through.
UofU Patient
January 12, 2020
HUNTSMAN CANCER CENTER
Dr Stephens is a wonderful doctor, friendly, caring, and compassionate.
UofU Patient
January 11, 2020
HUNTSMAN CANCER CENTER
I appreciate everyone taking the time for questions and answers and concerns. I didn't feel rushed.
UofU Patient
January 10, 2020
HUNTSMAN CANCER CENTER
She is always explaining in detail, listening to and answering concerns.
UofU Patient
December 20, 2019
HUNTSMAN CANCER CENTER
Both Stephens and Lowrance are fabulous to work with.
UofU Patient
December 11, 2019
HUNTSMAN CANCER CENTER
good
UofU Patient
December 04, 2019
HUNTSMAN CANCER CENTER
Dr. Stephens is very attentive and listens to my concerns. I hope I never have to refer or recommend anyone else but will do so without hesitation if it is necessary.
Languages Spoken: English, Spanish
Deborah Stephens, DO joined the Division of Hematology and Hematologic Malignancies as an Assistant Professor in 2014. She completed her internal medicine residency at Cleveland Clinic and fellowship training at Ohio State University. Dr. Stephens’s clinic focuses on patients with chronic lymphocytic leukemia (CLL) and lymphoma. Her primary research interests include developing new targeted therapies for patients with CLL and lymphoma, studying resistance to current therapies, and developing supportive therapies for complications of CLL.. She is the Physician Leader of the Hematology Clinical Trials Division at Huntsman Cancer Institute and is the principal investigator on multiple clinical trials there. Her research has been widely published in influential journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. She is a member of the editorial board for the Journal of Clinical Oncology. On a national level, she is an expert panelist for the National Comprehensive Cancer Network (NCCN) CLL Guidelines Panel, which establishes and published the most widely referenced guidelines for the evaluation and treatment of patients with CLL. Dr. Stephens is the Physician Leader of the SWOG CLL Working Group Committee, which is a group of CLL experts from academic centers around the country who plan and implement national clinical trials to improve the standard-of-care for CLL patients across the country. Dr. Stephens is also a member of the medical board for the CLL Society, which is the largest patient-led CLL group in the country. The sum of Dr. Stephens's experiences demonstrate her deep commitment to improve the care of patients with CLL and lymphoma.
Academic Locations
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor |
| Academic Divisions | Hematology/BMT |
| Board Certification | American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) |
Education History
| Fellowship | The Ohio State University Medical Center Hematology & Oncology Chief Fellow, 2014 |
| Residency | The Ohio State University Internal Medicine Resident, 2010 |
| Residency | Cleveland Clinic Internal Medicine Resident, 2009 |
| Professional Medical | Kansas City University of Medicine Osteopathic Medicine D.O., 2007 |
| Undergraduate | The University of Iowa Health Sciences B.S., 2003 |
Selected Publications - Journal Articles
Journal Article
- Stephens DM, Boucher K, Kander E, Parikh SA, Parry EM, Shadman M, Pagel JM, Cooperrider J, Rhodes J, Mato A, Winter A, Hill B, Gaballa S, Danilov A, Phillips T, Brander DM, Smith SM, Davids M, Rogers K, Glenn MJ, Byrd JC (2021). Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica, 106(11), 2845-2852.
- Furman RR, Byrd JC, Owen RG, OBrien SM, Brown JR, Hillmen P, Stephens DM, Chernyukhin N, Lezhava T, Hamdy AM, Izumi R, Patel P, Baek M, Christian B, Dyer MJS, Streetly MJ, Sun C, Rule S, Wang M, Ghia P, Jurczak W, Pagel JM, Sharman JP (2021). Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia, 35(11), 3201-3211.
- Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason JE, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG (2021). Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. (Epub ahead of print) Blood.
- Stephens DM, Byrd JC (2020). Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. Blood, 138(13), 1099-1109.
- Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR (2021). Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. (Epub ahead of print) Haematologica.
- Orellana-Noia VM, Reed D, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins MP, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers AA, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law JY, Karmali R, Shah HR, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko JM, Cohen JB, Portell CA (2021). Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. (Epub ahead of print) Blood.
- Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, Salous T, Hill BT, Alqahtani H, Choi M, Churnetski MC, Cohen JB, Stephens DM, Siddiqi T, Rivera X, Persky D, Wisniewski P, Patel K, Shadman M, Park B, Danilov AV (2021). The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. Clin Cancer Res, 27(17), 4814-4824.
- Byrd JC, Woyach JA, Furman RR, Martin P, OBrien S, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG (2020). Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood, 137(24), 3327-3338.
- Kittai AS, Huang Y, Gordon M, Denlinger N, Mian A, Fitzgerald L, Bishop J, Nagle S, Stephens DM, Jaglowski S, Hill B, Danilov AV (2020). Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. Biol Blood Marrow Transplant, 27(1), 46-52.
- Feusier JE, Madsen MJ, Avery BJ, Williams JA, Stephens DM, Hu B, Osman AEG, Glenn MJ, Camp NJ (2021). Shared genomic segment analysis in a large high-risk chronic lymphocytic leukemia pedigree implicates CXCR4 in inherited risk. J Transl Genet Genom, 5, 189-199.
- Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, Barr PM, Winegarden JD 3rd, Constine LS, Fitzgerald TJ, Leonard JP, Kahl BS, LeBlanc ML, Song JY, Fisher RI, Rimsza LM, Smith SM, Miller TP, Friedberg JW (2020). Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. J Clin Oncol, 38(26), 3003-3011.
- Koffman B, Mato A, Byrd J, Danilov A, Hedrick B, Ujjani C, Roeker L, Stephens DM, Davids M, Pagel JM, Shadman M (2020). A survey of CLL experts opinion on management of patients during the COVID-19 pandemic. J Clin Oncol, E199-E203..
- Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Burke K, Covey T, Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, OBrien S, Furman RR (2018). Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood, 135(15), 1204-1213.
- Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer MA, Sundar H (2020). Chronic lymphocytic leukemia/small lymphocytic lymphoma, Version 4.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 18(2), 185-217.
- Gordon MJ, Sitlinger A, Salous T, Alqahtani H, Churnetski M, Rivera X, Wisniewski P, Cohen J, Patel K, Shadman M, Choi M, Hill B, Stephens DM, Persky D, Brander D, Danilov AD (2020). A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: results from a multicenter retrospective cohort study. Leuk Res Treatment, 89.
- Stephens DM (2019). Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia. Blood, 134(20), 1691-1696.
- Stephens DM, Li H, Schder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi ED, Leonard JP, Kahl BS, Smith SM, Friedberg JW (2019). Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood, 134(15), 1238-1246.
- Geer M, Roberts E, Shango M, Till BG, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips TJ (2019). Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. Br J Haematol, 186(2), 255-262.
- Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Woyach J, Bibikova E, Charuworn P, Frigault MM, Hamdy A, Izumi R, Linghu B, Patel P, Wang MH, Byrd JC (2018). Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv, 3(9), 1553-1562.
- Stephens DM, Byrd JC (2019). How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood, 133(12), 1298-1307.
- Stephens DM (2019). Highs and lows of minimal residual disease in CLL. Blood, 133(5), 386-388.
- Havard R, Stephens DM (2018). Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma. Curr Hematol Malig Rep, 13(6), 534-542.
- Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H (2017). Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15, 1414-1427.
- Giulino-Roth L, ODonohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP (2017). Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol, 179(5), 739-747.
- Stephens DM (2017). Brentuximab: is it time for a new "B" in ABVD? Blood, 130(11), 1281-1282.
- Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM (2017). PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood, 130(2), 221-228.
- Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Woyach J, Bibikova E, Charuworn P, Frigault MM, Hamdy A, Izumi R, Linghu B, Patel P, Wang MH, Byrd JC (2016). Acalabrutinib monotherapy in patients with ibrutinib intolerance: results from the phase 1/2 ACE-CL-001 clinical study. Blood, 128(22), 638.
- Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW (2016). Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation. Oncology (Williston Park), 30(11), 970-4, 980-1, C3.
- Haverkos BM, Schowinksy J, Kaplan J, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Flowers MED, Fensky TS, Hari P, Hamadani M, Lowsky R, Andritsos L, Jagasia MH, Brown S, Armand P, Merryman RW, Bachanova V, Stephens DM, Nakamura R, Gutman JA, Devine SM (2016). Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease. Blood, 128(22), 1163.
- Stephens DM, Li H, LeBlanc ML, Puvvada SD, Persky D, Friedberg JW, Smith SM (2016). Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. J Clin Oncol, 34(25), 2997-3004.
- Luo C, Deng Z, Li L, Clayton F, Chen AL, Wei R, Miles R, Stephens DM, Glenn M, Wang X, Jensen PE, Chen X (2016). Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells. Oncotarget, 7(11), 12806-22.
- Byrd JC, Harrington B, OBrien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR (2016). Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med, 374(4), 323-32.
- Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, OBrien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC (2015). Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. Am J Hematol, 90(11), 967-9.
- Stephens DM, Spurgeon SE (2015). Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Ther Adv Hematol, 6(5), 242-52.
- Miller CR, Stephens D, Ruppert AS, Racke F, McFaddin A, Breidenbach H, Lin HJ, Waller K, Bannerman T, Jones JA, Woyach JA, Andritsos LA, Maddocks K, Zhao W, Lozanski G, Flynn JM, Grever M, Byrd JC, Heerema NA (2015). Jumping translocations, a novel finding in chronic lymphocytic leukaemia. Br J Haematol, 170(2), 200-7.
- Rogers KA, Salem G, Stephens DM, Andritsos LA, Awan FT, Byrd JC, Flynn JM, Maddocks KJ, Huang Y, Ruppert AS, Jones JA (2015). A single-institution retrospective cohort study of patients treated with R-EPOCH for Richter’s transformation of chronic lymphocytic leukemia. Blood, 126(23), 2951.
- Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC (2014). Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. Leukemia, 28(6), 1365-8.
- Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, OReilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JC (2014). Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. mAbs, 6(3), 749-55.
- Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JM (2013). Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leuk Res, 37(10), 1195-9.
- Stephens DM, Stark A, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC (2013). Changing the treatment paradigm for previously treated chronic lymphocytic leukemia patients with del(17p) karyotype. Blood, 122(21), 2872.
- Stephens DM, Byrd JC (2013). Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches. Oncology (Williston Park), 26(11), 1044-54.
- Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, Byrd JC (2012). Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica, 97(3), 423-7.
- Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, and Byrd JC (03/01/2012). Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica, 97(3), 423-427.
- Mickelson DM, Sproat L, Dean R, Sobecks R, Rybicki L, Kalaycio M, Pohlman B, Sweetenham J, Andresen S, Bolwell B, Copelan EA (2011). Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT. Bone Marrow Transplant, 46(1), 84-9.
- Mickelson DM, Hatem S, and Copelan E (02/01/2010). Granulocyte Simulating-Colony Factor-Associated Splenic Artery Rupture. Leuk Lymphoma, 51(2), 335-337.
Review
- Stephens DM, Byrd JC (2020). Next-Generation Bruton Tyrosine Kinase Inhibitors. [Review]. Am J Clin Oncol, JCO2001594.
- Shadman M, Stephens DM (2020). Debate: What is optimal first-line therapy for chronic lymphocytic leukemia? [Review]. J Natl Compr Canc Netw, 18(7.5), 993-997.
- Stephens DM, Byrd JC (2019). How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. . [Review]. Blood, 133(12), 1298-1307.
- Stephens DM, Smith SM (2018). Diffuse large B-cell lymphoma-Who should we FISH? [Review]. Ann Lymphoma, 2, 2616-2695.
- Voorhies BN, Stephens DM (2017). What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017? [Review]. Curr Treat Options Oncol, 18(2), 12.
- Stephens DM, Goodrich AL (2016). Risk-Stratified Treatment in Chronic Lymphocytic Leukemia. [Review]. J Adv Pract Oncol, 7(3), 314-317.
- Stephens DM, Sweetenham JW (04/11/2015). Clinical controversies of double-hit lymphoma. [Review]. Am J Hematol Oncol, 11(4), 10-16.
- Stephens DM, Byrd JC (2013). Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy. [Review]. Hematol Oncol Clin North Am, 27(2), 303-27.
- Stephens DM, Byrd JC (11/1/2012). Chronic lymphocytic leukemia with del(17p13.1): A distinct clinical subtype requiring novel treatment approaches. [Review]. Oncology, 11, 1044-1054.
- Stephens DM, Byrd JC (2012). Ask the hematologists: Is there a standard of care for treating older patients with chronic lymphocytic leukemia? [Review]. The Hematologist, 9(4), 4.
- Stephens DM, Byrd JC (2012). Chronic lymphocytic leukemia with del(17p13.1): a distinct clinical subtype requiring novel treatment approaches. [Review]. Oncology, 26(11), 1044-1054.
- Mickelson DM, Mady E, and Teng K (2009). A 43 year-old woman with chest pressure: a review of hypercoagulable states. [Review]. Cleve Clin J Med, 76(3), 191-8.
- Shah H, Stephens DM, Seymour J, Maddocks K (Pending). Incorporating novel targeted and immunotherapeutic agents in treatment of B-cell lymphomas. 2021 Feb. Accepted for publication. [Review]. J Clin Oncol.
Conference Proceedings
- Haverkos BM, Schowinksy J, Kaplan JB, Kamdar M, Kanate AS, Saad A, Ganguly S, Flowers M, Fenske TS, Hari P, Hamadani M, Lowsky R, Andritsos L, Jagasia M, Brown S, Armand P, Merryman R, Bachanova V, Stephens DM, Nakumura R, Gutman J, Devine SM (12/03/2016). Checkpoint blockade for treatment of lymphoma following allogeneic stem cell transplant: use may be complicated by onset of severe acute graft versus host disease. American Society of Hematology Meeting, San Diego.
- Stephens DM, Starodub AN, Byrd JC, Wegener, WA, Horne H, Goldenberg, DM, Christian BA (07/15/2016). Subcutaneous injections of IMMU-114 (anti-HLA-DR IgG4 monoclonal antibody): Initial results of a phase I first-in-man study in hematologic malignancies. Pan-Pacific Lymphoma Conference, Poipu, Hawaii.
- Byrd JC, Jones JA, Furman RR, Stephens DM, Devereux S, Brown JR, Hillmen P, Hamdy AM, Wang MH, Patel P, Mittag D, Krantz M, Rothbaum W, Izumi R, OBrien SM, Wierda WG (06/15/2016). Acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, in previously untreated chronic lymphocytic leukemia. American Society of Clinical Oncology Annual Meeting, Chicago.
- Stephens DM, Starodub AN, Byrd JC, Wegener, WA, Horne H, Goldenberg, DM, Christian BA (12/01/2015). Subcutaneous injections of IMMU-114 (anti-HLA-DR IgG4 monoclonal antibody): Initial results of a phase I first-in-man study in hematologic malignancies. Orlando, Florida: American Society of Hematology Meeting.
- Stephens DM, LeBlanc ML, Li H, Miller TP, Puvvada SD, Persky D, Friedberg J, Smith SM (06/19/2015). Continued risk of relapse independent of treatment modality in limted stage diffuse large B-cell lymphoma: Final and long-term analysis of SWOG study S8736. 13th International Conference on Malignant Lymphoma, Lugano, Switzerland.
- Stephens DM, Stark A, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC (2013). Changing the treatment paradigm for previously treated chronic lymphocytic leukemia patients with del(17p) karyotype. New Orleans, LA: American Society of Hematology Meeting.
- Stephens DM, Cheney CM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, OReilly A, Ramachandran A, Tidandapani S, Muthusamy N, and Byrd JC (2013). Ocaratuzumab, a proposed effective and convenient alternative for treatment of chronic lymphocytic leukemia. Cologne, Germany: International Workshop on Chronic Lymphocytic Leukemia.
- Stephens DM, Ruppert AS, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Jones JA, Flynn JM, Grever MR, Hareema N, Muthusamy N, and Byrd JC (06/01/2013). Predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. Stockholm, Sweden: European Hematology Association International Congress.
- Stephens DM, Maddocks K, Andritsos L, Baiocchi R, Jones J, Phelps M, Johnson AJ, Smith L, Grever MR, Byrd JC, and Flynn JM (06/01/2012). Phase I feasibility trial of cyclophosphamide, alvocidib (flavopiridol) and rituximab in patients with high-risk b-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Amsterdam, Netherlands: European Hematology Association International Congress.
- Mickelson D, Sproat L, Dean R, Sobecks R, Rybicki L, Kalaycio M, Pohlman B, Sweetenham J, Andresen S, Bolwell B, and Copelan E (02/01/2009). T-cell engraftment kinetics following myeloablative and nonmyeloablative regimens for allogeneic hematopoietic stem-cell transplantation. Tampa, Florida: American Society for Blood and Marrow Transplantation.
Commentary
- Stephens DM (2017). Brentuximab: is it time for a new "B" in ABVD? Blood, 130(11), 1281-1282.
- Stephens DM (2016). Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia: An Archaic Intervention or a Necessary Evil? Oncology (Williston Park), 30(6), 539-40.
Case Report
- Fitzgerald L, Stephens DM (2020). Burkitt Lymphoma Presenting as Cranial Multineuritis Secondary to Primary Neurolymphomatosis: A Diagnostic Challenge. Clin Lymphoma Myeloma Leuk, 20(4), e201-e204.
- Laggis C, Miles R, Stephens DM, Duffy K, Bowen A, Wada D (2019). Cutaneous mantle cell lymphoma histomorphologically mimicking subcutaneous panniculitis-like T-cell lymphoma: Case report. J Cutan Pathol, 46(7), 538-541.
- Juster-Switlyk K, Smith AG, Kovacsovics T, Stephens D, Glenn M, Palmer CA, Quigley EP 3rd, Kolb N (2017). MTHFR C677T polymorphism is associated with methotrexate-induced myelopathy risk. Neurology, 88(6), 603-604.
Editorial
Letter
- Stephens DM, Schoder H, Li H, Friedberg J (2020). Reply: Interim PET Assessment of Advanced Hodgkin Lymphoma: Is It Sufficient? [Letter to the editor]. J Nucl Med, 61(11), 1695.
- Koffman B, Mato A, Byrd JC, Danilov A, Hedrick B, Ujjani C, Roeker L, Stephens DM, Davids MS, Pagel JM, Shadman M (2020). Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. [Letter to the editor]. Am J Hematol, 95(8), E199-E203.
Abstract
- Giulino-Roth L, ODonohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberlye MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP (2017). Outcomes of adults, adolescents, and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R therapy: a multicenter retrospective analysis [Abstract]. Hematological Oncology, 35(S2), 61-2.
- Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Hamdy A, Huang J, Izumi R, Patel P, Wang MH, Byrd JC (12/03/2016). Acalabrutinib monotherapy in patients with ibrutinibi: results from the phase 1/2 ACE-CL-001 clinical study [Abstract]. Blood, 128(22), 638.
- Stephens DM, Ruppert AS, Christian B, Jones J, Flynn JM, Porcu P, Baiocchi R, Byrd JC, Dotson EK, Crawford BS, and Blum KA (2012). Toxicity in patients 65 years with dose adjusted REPOCH for untreated diffuse large B cell lymphoma [Abstract]. Journal of Clinical Oncology, 30(suppl), 15.